US FDA expands use of Bristol Myers' cancer therapy (March 14)

The U.S. Food and Drug Administration on Thursday expanded the use of Bristol Myers Squibb's cell therapy, Breyanzi, for a type of slow-growing blood cancer, marking the third approval for the treatment.